Welcome!

News Feed Item

3-V Biosciences Presents Positive Preclinical Data on HCV Product Candidates Targeting FASN at the American Association for the Study of Liver Disease Annual Meeting 2012

Small Molecule FASN Inhibitors Demonstrate Antiviral Activity

MENLO PARK, Calif., Nov. 10, 2012 /PRNewswire/ -- 3-V Biosciences, Inc., announced today that preclinical data for its novel fatty acid synthase (FASN) inhibitors for the treatment of chronic hepatitis C virus (HCV) infection will be presented at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases (The Liver Meeting®) being held November 9-13 in Boston, Massachusetts. 

(Logo:  http://photos.prnewswire.com/prnh/20121001/LA83573LOGO)

"New, potent therapeutics that combine with and improve on the evolving standard of care for the treatment of hepatitis C infection are needed to ensure that we can reach the broadest population of patients with appropriate, curative regimens," said George Kemble, Chief Scientific Officer of 3-V Biosciences.  "3-V's FASN inhibitors represent an entirely new class of therapy.  With a novel mechanism of action, and broad-spectrum, potent antiviral activity demonstrated across multiple preclinical studies, we believe that our FASN inhibitors will bring substantial benefits to patients as a key component in emerging multi-drug treatment regimens.  We look forward to initiating clinical studies early next year."

Novel FASN Inhibitors
3-V's FASN inhibitors for the treatment of HCV are designed to have broad-spectrum activity, a high barrier to resistance and the ability to combine with direct-acting antivirals, such as nucleotide/nucleoside inhibitors, protease inhibitors, NS5a inhibitors and other mechanisms of action currently in development.  Data characterizing the preclinical antiviral activity of 3-V's FASN inhibitors will be featured in oral and poster presentations during The Liver Meeting.  Highlights of these data include:

  • Orally bioavailable representative molecules are potent and specific, with IC50s in the 5-50nM range;
  • Inhibitors have demonstrated excellent exposure and low toxicity in rodents associated with prolonged in vivo suppression of FASN;
  • Antiviral activity against wild-type Genotype 1a, 1b and 2a replicons; and
  • Antiviral activity against mutant HCV replicons resistant to NS3, NS4b, NS5a and NS5b inhibitors.

3-V's FASN inhibitors are a chemically diverse set of potent, specific, reversible molecules with an excellent range of pharmaceutical properties.  The company has filed multiple worldwide patent applications covering these inhibitors.  3-V's HCV program is on track for an IND in the first quarter of 2013 and the company anticipates clinical proof-of-concept data by year-end 2013.

Data describing 3-V's FASN inhibitor preclinical activity will be presented by Dr. Kemble during Sunday's HCV Therapy: Preclinical and Early Clinical Development parallel session at 5:30 pm in a talk titled: "Potent Hepatitis C Antiviral Activity By Inhibiting Fatty Acid Synthase" (Abstract #88).  A poster, "TVB-2640, a Novel Anti-HCV Agent, Safely Causes Sustained Host-Target Inhibition in Vivo" (Abstract #1876), describing mechanism and activity for one of 3-V's compounds will be presented on Tuesday, November 13 during the HCV Therapy: Preclinical and Early Clinical Development poster session from 8:00 a.m. to 12:00 p.m.

About FASN
FASN is a cellular enzyme implicated in HCV replication and several cancers.  First-generation FASN inhibitors have shown preclinical benefits in a variety of viral infections, including HCV, as well as in models of pancreatic, prostatic, breast and colorectal tumors, but their development has been hindered by poor bioavailability and systemic tolerability.  3-V has discovered and is advancing proprietary FASN inhibitors with pharmaceutical properties that overcome the shortcomings of earlier generations of inhibitors, and have the potential to become significant new approaches to the treatment of chronic HCV and other indications.

About 3-V Biosciences
3-V Biosciences, Inc. is a privately held biopharmaceutical company that discovers and develops antiviral therapeutics designed to have broad-spectrum activity, including efficacy against viruses resistant to other classes of antiviral drugs, and a high barrier to resistance.  The 3-V team applies an integrated approach with internal expertise in virology, biology, drug discovery and development to drive programs forward.  The company is located in Menlo Park, California.

For additional information on 3-V Biosciences, please visit www.3vbio.com.

Contact information

Stephen R. Brady
Chief Business Officer
650-561-8600

Media Inquiries

BCC Partners on behalf of 3-V Biosciences, Inc.
Karen L. Bergman
650-575-1509
[email protected]

Michelle Corral
415-794-8662
[email protected]

SOURCE 3-V Biosciences, Inc.

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
The IoT is changing the way enterprises conduct business. In his session at @ThingsExpo, Eric Hoffman, Vice President at EastBanc Technologies, discuss how businesses can gain an edge over competitors by empowering consumers to take control through IoT. We'll cite examples such as a Washington, D.C.-based sports club that leveraged IoT and the cloud to develop a comprehensive booking system. He'll also highlight how IoT can revitalize and restore outdated business models, making them profitable...
SYS-CON Events announced today that Alert Logic, Inc., the leading provider of Security-as-a-Service solutions for the cloud, will exhibit at SYS-CON's 18th International Cloud Expo®, which will take place on June 7-9, 2016, at the Javits Center in New York City, NY. Alert Logic, Inc., provides Security-as-a-Service for on-premises, cloud, and hybrid infrastructures, delivering deep security insight and continuous protection for customers at a lower cost than traditional security solutions. Ful...
The essence of data analysis involves setting up data pipelines that consist of several operations that are chained together – starting from data collection, data quality checks, data integration, data analysis and data visualization (including the setting up of interaction paths in that visualization). In our opinion, the challenges stem from the technology diversity at each stage of the data pipeline as well as the lack of process around the analysis.
Many banks and financial institutions are experimenting with containers in development environments, but when will they move into production? Containers are seen as the key to achieving the ultimate in information technology flexibility and agility. Containers work on both public and private clouds, and make it easy to build and deploy applications. The challenge for regulated industries is the cost and complexity of container security compliance. VM security compliance is already challenging, ...
Designing IoT applications is complex, but deploying them in a scalable fashion is even more complex. A scalable, API first IaaS cloud is a good start, but in order to understand the various components specific to deploying IoT applications, one needs to understand the architecture of these applications and figure out how to scale these components independently. In his session at @ThingsExpo, Nara Rajagopalan is CEO of Accelerite, will discuss the fundamental architecture of IoT applications, ...
SYS-CON Events announced today that Commvault, a global leader in enterprise data protection and information management, has been named “Bronze Sponsor” of SYS-CON's 18th International Cloud Expo, which will take place on June 7–9, 2016, at the Javits Center in New York City, NY, and the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Commvault is a leading provider of data protection and information management...
SYS-CON Events announced today that Tintri Inc., a leading producer of VM-aware storage (VAS) for virtualization and cloud environments, will exhibit at the 18th International CloudExpo®, which will take place on June 7-9, 2016, at the Javits Center in New York City, New York, and the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
With major technology companies and startups seriously embracing IoT strategies, now is the perfect time to attend @ThingsExpo 2016 in New York and Silicon Valley. Learn what is going on, contribute to the discussions, and ensure that your enterprise is as "IoT-Ready" as it can be! Internet of @ThingsExpo, taking place Nov 3-5, 2015, at the Santa Clara Convention Center in Santa Clara, CA, is co-located with 17th Cloud Expo and will feature technical sessions from a rock star conference faculty ...
Companies can harness IoT and predictive analytics to sustain business continuity; predict and manage site performance during emergencies; minimize expensive reactive maintenance; and forecast equipment and maintenance budgets and expenditures. Providing cost-effective, uninterrupted service is challenging, particularly for organizations with geographically dispersed operations.
As cloud and storage projections continue to rise, the number of organizations moving to the cloud is escalating and it is clear cloud storage is here to stay. However, is it secure? Data is the lifeblood for government entities, countries, cloud service providers and enterprises alike and losing or exposing that data can have disastrous results. There are new concepts for data storage on the horizon that will deliver secure solutions for storing and moving sensitive data around the world. ...
SYS-CON Events announced today that AppNeta, the leader in performance insight for business-critical web applications, will exhibit and present at SYS-CON's @DevOpsSummit at Cloud Expo New York, which will take place on June 7-9, 2016, at the Javits Center in New York City, NY. AppNeta is the only application performance monitoring (APM) company to provide solutions for all applications – applications you develop internally, business-critical SaaS applications you use and the networks that deli...
SYS-CON Events announced today that MangoApps will exhibit at SYS-CON's 18th International Cloud Expo®, which will take place on June 7-9, 2016, at the Javits Center in New York City, NY. MangoApps provides modern company intranets and team collaboration software, allowing workers to stay connected and productive from anywhere in the world and from any device. For more information, please visit https://www.mangoapps.com/.
18th Cloud Expo, taking place June 7-9, 2016, at the Javits Center in New York City, NY, will feature technical sessions from a rock star conference faculty and the leading industry players in the world. Cloud computing is now being embraced by a majority of enterprises of all sizes. Yesterday's debate about public vs. private has transformed into the reality of hybrid cloud: a recent survey shows that 74% of enterprises have a hybrid cloud strategy. Meanwhile, 94% of enterprises are using some...
SoftLayer operates a global cloud infrastructure platform built for Internet scale. With a global footprint of data centers and network points of presence, SoftLayer provides infrastructure as a service to leading-edge customers ranging from Web startups to global enterprises. SoftLayer's modular architecture, full-featured API, and sophisticated automation provide unparalleled performance and control. Its flexible unified platform seamlessly spans physical and virtual devices linked via a world...
In his keynote at 18th Cloud Expo, Andrew Keys, Co-Founder of ConsenSys Enterprise, will provide an overview of the evolution of the Internet and the Database and the future of their combination – the Blockchain. Andrew Keys is Co-Founder of ConsenSys Enterprise. He comes to ConsenSys Enterprise with capital markets, technology and entrepreneurial experience. Previously, he worked for UBS investment bank in equities analysis. Later, he was responsible for the creation and distribution of life ...